- Policy
- COVID-19 vaccine release time can be judged in phase III
- by Lee, Hye-Kyung Aug 4, 2020 05:54am
- With the time to release the COVID-19 vaccine, a domestic expert said that it is not yet in the stage of discussion. Mook Hyun-sang, the head of Korea Drug Development Fund (KDDF) announced the results at the future open discussion with the theme of 'COVID-19 vaccine, global development trend and securing strategy' co-sponsored by the MO
- Company
- Sales of Duvie exceeded ₩10 billion in the first half
- by Chon, Seung-Hyun Aug 4, 2020 05:54am
- Chong Kun Dang's developed diabetes drug 'Duvie' exceeded the prescription record of &8361;10 billion in the first half. It is strengthening its market competitiveness with the combination drug 'Duvimet'. According to UBIST on the 31st, the total amount of outpatient prescriptions for Duvie in June increased by 5.9% year-on-year to &8361;1
- Company
- Study of Statins vs Ezetimibe combination therapy is ongoing
- by Eo, Yun-Ho Aug 3, 2020 11:06am
- Studies are being conducted to directly compare Statin monotherapy and Ezetimibe combination therapy to Koreans. Yang-Soo Jang, professor at Yonsei University Severance Hospital, conducted a study comparing the efficacy of high-dose Statins and Ezetimibe combination therapy in primary therapy in patients with dyslipidemia with cardiovascul
- Company
- Next-gen Vemlidy prescription grows solely amid COVID-19
- by Kim, Jin-Gu Aug 3, 2020 11:06am
- The outpatient prescription sales of Gilead Science’s hepatitis B treatment Vemlidy (tenofovir) has gone up by 56 percent compared to the second quarter last year. Although the hepatitis B virus (HBV) infection treatment market size has shrunk amid COVID-19 pandemic, Vemlidy has performed at a satisfying level and salvaged the fall Vire
- Policy
- Recruitment of 733 COVID-19 cured patients was completed
- by Lee, Hye-Kyung Aug 3, 2020 11:06am
- 1098 patients who were cured revealed their willingness to participate in the development of COVID-19 blood plasma, of which 733 were recruited. At the regular briefing held on the 30th, Kwon Jun-wook, Deputy director of the Central Disease Control Headquarters said, “Recruitment of 733 plasma for cured patients was completed and recovery
- Policy
- The promotion for the KCDC are in progress
- by Lee, Jeong-Hwan Aug 3, 2020 11:05am
- On the 28th, the Public Administration and Security Committee held a general meeting without any member of the opposition party, and decided to amend the government organizational law, which included the introduction of multiple vice ministers by the MOHW and the promotion of the KCDC to the Disease Control and Prevention Service. As a re
- Product
- Successful August KMA strike all depends on participation
- by Kang, Shin-Kook Aug 3, 2020 11:05am
- The doctors’ organization objecting against the South Korean government intending to expand medical school admission and provide coverage on Korean herbal medicine are drawing up a plan to call a private clinic doctors’ strike. The strike is most likely to be on Aug. 14. According to Korean Medical Association (KMA) on July 29, the issue o
- Company
- Generics for NOAC will be released
- by Kim, Jin-Gu Aug 2, 2020 09:47pm
- In the oral anticoagulant (NOAC) market, which forms a market of &8361;200 billion annually, the prescription performance of items other than Lixiana has decreased. Generics are gradually increasing sales. The competition in this market is expected to intensify if generics for Xarelto and Pradaxa are released next to generic for Eliquis next
- Company
- Choline alfoscerate companies anxious of returning claims
- by Chon, Seung-Hyun Jul 31, 2020 06:34am
- Companies with cognitive enhancer choline alfoscerate products are to face another hurdle. Specifically, the companies are concerned of the clause stipulating the return of the claimed reimbursement when failing the clinical reevaluation during the pricing renegotiation for a product surging in sales. As South Korea’s Ministry of Food and Drug
- Company
- LG Chem begins development of Zemiglo + SGLT-2 inhibitor
- by Kim, Jin-Gu Jul 31, 2020 06:33am
- LG Chem will develop a combination of DPP-4 inhibitor and SGLT-2 inhibitor. Currently, three items are permitted as a combination, but no drug has been developed by a domestic pharmaceutical company. According to the pharmaceutical industry on the 29th, the MFDS recently approved LG Chem's Phase I trial plan which comparing the pharmacokineti
